- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02834416
ADT Exercise Trial and Economic Analysis (ADTExRCT)
A Randomized Control Trial (RCT) and Economic Analysis of Two Exercise Delivery Methods in Men With Prostate Cancer on ADT
Prostate Cancer (PC) affects 1 in 7 men. Nearly half of those diagnosed with PC will receive androgen deprivation therapy (ADT) as part of their treatment. ADT is good at managing PC but has many side effects. Researchers have shown that exercise, specifically one-on-one supervised exercise improves many of the side effects of ADT. However, exercise programs for men on ADT are not widely available. More questions need to be answered in order for exercise programs to become part of PC treatment. First, can programs that require fewer resources, such as group-exercise or home-based exercise, also improve ADT side-effects? Second, do exercise-related benefits continue beyond the structured exercise program? And what makes people continue exercising? Third, which exercise program is most cost-effective?
In this study, the investigators will compare: (a) group supervised in-centre and (b) home-based supported exercise programs to see which program is most effective for men with PC on ADT. The investigators will also look at what motivates people to continue to exercise both during a structured program and after the program is complete and will examine which exercise program is most cost-effective.
Participants (men with PC on ADT) will be recruited from one of the following cancer centres: Princess Margaret Cancer Centre in Toronto, the Tom Baker Cancer Centre in Calgary, the Southlake Regional Health Centre in Newmarket, and Scarborough and Rouge Hospital - Centenary Site in Scarborough. When a patient agrees to participate, patient will be randomly placed in 1 of 2 exercise programs. All programs will include the same type of exercises (aerobic, resistance and flexibility) and all participants will exercise 4-5 days per week for 30 minutes per day (as tolerated) for the length of the program (6 months). The investigators will look at how men with PC on ADT respond to the exercise program by measuring quality of life (QOL), fatigue and different physical measures before, during, and after the exercise program.
Although the investigators know that supervised one-on-one exercise is most effective at improving ADT side-effects, it is unknown if other forms of exercise are just as beneficial and more financially responsible. This study will allow the investigators to begin to answer these questions so that structured exercise programs become a regular part of PC treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 1N4
- University of Calgary/Tom Baker Cancer Centre
-
-
Ontario
-
Newmarket, Ontario, Canada
- Southlake Regional Health Centre
-
Toronto, Ontario, Canada, M1P 2T7
- Scarborough and Rouge Hospital
-
Toronto, Ontario, Canada, M5G2C4
- Princess Margaret Cancer Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- men with histologically confirmed PC who are starting or continuing on ADT for at least 6 months or who are in an androgen-deprived (or castrate) state for the duration of the intervention
- fluent in English
- able to provide consent
- close to a study centre
Exclusion Criteria:
- already meeting guidelines for moderate to vigorous physical activity (MVPA) - conditions that would interfere with ability to participate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group-Supervised
This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist.
Supervised sessions will be delivered in a group format with 4-8 participants per group.
Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session.
Aerobic training will involve 30 minutes of low-impact step aerobics.
Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups.
Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
|
The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
|
Experimental: Home-Based
The same protocol and training frequency as the supervised programs described above will be followed.
However, all exercises will be completed independently by participants.
Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as the supervised group).
Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase.
This will help to ensure participant adherence, appropriate progression, and safety.
|
The exercise program will be executed independently by participants in a home-based setting.
Home-based participants will be supported with remote health coaching and smartphone technology.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional Assessment of Cancer Therapy-Fatigue (FACT-F)
Time Frame: Every 3 Months for 12 Months
|
The FACT-F is a questionnaire that includes 13 items measuring cancer-related fatigue.
|
Every 3 Months for 12 Months
|
6 Minute Walk Test (6MWT)
Time Frame: Every 3 Months for 12 Months
|
The 6MWT is a commonly used, validated measure that assesses functional endurance.
|
Every 3 Months for 12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional Assessment of Cancer Therapy-General (FACT-G)
Time Frame: Every 3 Months for 12 Months
|
The FACT-G is a questionnaire that is well-validated and widely used to measure quality of life (QOL).
|
Every 3 Months for 12 Months
|
Functional Assessment of Cancer Therapy-Prostate (FACT-P)
Time Frame: Every 3 Months for 12 Months
|
The FACT-P is a questionnaire that supplements the FACT-G with 12 prostate-specific items covering domains of urinary function, sexual function, pain, and related symptoms.
|
Every 3 Months for 12 Months
|
5 Times Sit to Stand Test
Time Frame: Every 3 Months for 12 Months
|
A common, simple, and validated measure of functional lower body strength.
|
Every 3 Months for 12 Months
|
Grip Strength
Time Frame: Every 3 Months for 12 Months
|
Grip strength is a measure of upper body strength and predicts long-term disability and mortality in middle-aged and older adults.
|
Every 3 Months for 12 Months
|
Bioelectrical Impedance Analysis
Time Frame: Every 6 Months for 12 Months
|
Body composition will be measured using bioelectrical impedance analysis (BIA).
|
Every 6 Months for 12 Months
|
Waist Circumference and Hip Ratio
Time Frame: Every 6 Months for 12 Months
|
Body composition will be measured using waist circumference(WC) and WC:hip ratio, following the standardized Canadian Society for Exercise Physiology - Physical Activity Training for Health (CSEP-PATH) protocol.
|
Every 6 Months for 12 Months
|
Body Mass Index
Time Frame: Every 6 Months for 12 Months
|
Body composition will be measured using body mass index (BMI).
|
Every 6 Months for 12 Months
|
Bone Mineral Density (BMD)
Time Frame: Every 6 Months for 12 Months
|
Bone mineral density will be measured at lumbar spine, hip, and distal 1/3 radius using dual x-ray absorptiometry (DXA).
|
Every 6 Months for 12 Months
|
Biological Outcomes (blood work)
Time Frame: Every 6 Months for 12 Months
|
Fasting lipids, blood glucose, glycated hemoglobin, hemoglobin, prostate-specific antigen (PSA), and testosterone will be measured.
Serum banking will also be done for use in future studies.
|
Every 6 Months for 12 Months
|
Sedentary Behaviour
Time Frame: Every 6 Months for 12 Months (unless otherwise specified)
|
Time spent in activities that are characterized by an energy expenditure ≤ 1.5 metabolic equivalents and a sitting or reclining posture (sedentary behavior) will be assessed using the Sedentary Behaviour Questionnaire that is used in large cohort studies and has demonstrated evidence of reliability and validity.
|
Every 6 Months for 12 Months (unless otherwise specified)
|
Planning, Attitudes, & Barriers scale
Time Frame: Every 6 Months for 12 Months (unless otherwise specified)
|
The Planning, Attitudes, & Barriers scale is a validated questionnaire that will be used to assess likelihood of exercise behavior over time.
|
Every 6 Months for 12 Months (unless otherwise specified)
|
Behavioral Regulations in Exercise Questionnaire-2 (BREQ-2)
Time Frame: Every 6 Months for 12 Months (unless otherwise specified)
|
Behavioral Regulations in Exercise Questionnaire-2 (BREQ-2) is a validated questionnaire that assess predictors of adherence.
|
Every 6 Months for 12 Months (unless otherwise specified)
|
Psychological Need Support and Frustration Scale - Relatedness Items
Time Frame: Every 6 Months for 12 Months (unless otherwise specified)
|
Relatedness will be assessed using the Psychological Need Support and Frustration Scale - Relatedness Items.
|
Every 6 Months for 12 Months (unless otherwise specified)
|
Health Care Climate Questionnaire (HCCQ)
Time Frame: Baseline only
|
The Health Care Climate Questionnaire (HCCQ short form) assess participant perceptions of their health care team.
|
Baseline only
|
Walkability
Time Frame: Baseline only
|
Participant postal codes will be collected to assess neighbourhood walkability (i.e., access to a grocery store within walking distance).
|
Baseline only
|
Disease-related Costs
Time Frame: Every 3 Months for 12 Months
|
The investigators will collect economically relevant data about health status using preference-based (utility) instruments (European Quality of Life Five Dimensions Questionnaire, EQ-5D).
Productivity losses and out-of-pocket expenditures, in addition to hospitalization, drug co-pay, and health visit data will be gathered using a patient questionnaire.
|
Every 3 Months for 12 Months
|
Exercise Adherence
Time Frame: Every 3 Months for 12 Months
|
Both accelerometry and the Godin Leisure Time Exercise Questionnaire will be used as a measure of adherence at each time point.
Both measures will provide a validated measure of physical activity.
|
Every 3 Months for 12 Months
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-8158-CE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Supervised Group Exercise
-
Hasselt UniversityRecruitingGestational Hypertension | Cardiovascular Pregnancy ComplicationBelgium
-
University Health Network, TorontoCompletedProstate CancerCanada
-
Universidad Politecnica de MadridUnknown
-
Mehmet Akif Ersoy UniversityAkdeniz UniversityCompletedExercise Program | Type2diabetesTurkey
-
United Arab Emirates UniversityMohammed Bin Rashid University of Medicine and Health SciencesCompletedCardiovascular Risk Factor | Pre Diabetes | High Blood Pressure | Elevated LDL CholesterolUnited Arab Emirates
-
Klaus WidhalmOrthopedic Hospital Vienna SpeisingRecruitingHip ReplacementAustria
-
Istanbul University - Cerrahpasa (IUC)RecruitingMultiple SclerosisTurkey
-
University of WaterlooUniversity Health Network, Toronto; Canadian Institutes of Health Research... and other collaboratorsRecruiting
-
Dr. John BartlettSligo General Hospital; Institute of Technology, SligoUnknown
-
Universidade Federal de Santa MariaCompletedOsteoarthritis, KneeBrazil